monoclon
antibodi
mab
revolution
diagnosi
treatment
mani
human
diseas
applic
combin
mab
demonstr
improv
therapeut
activ
preclin
clinic
test
combin
antibodi
sever
advantag
capac
target
multipl
mutat
antigen
complex
pathogen
engag
vari
epitop
multipl
diseaserel
antigen
eg
receptor
overcom
heterogen
plastic
oligoclon
antibodi
emerg
therapeut
format
novel
antibodi
combin
develop
singl
drug
product
provid
histor
context
use
oligoclon
antibodi
oncolog
infecti
diseas
highlight
practic
consider
relat
preclin
clinic
develop
program
david
corti
jeffrey
kearn
monoclon
antibodi
mab
revolution
diagnosi
treatment
mani
human
diseas
applic
combin
mab
demonstr
improv
therapeut
activ
preclin
clinic
test
combin
antibodi
sever
advantag
capac
target
multipl
mutat
antigen
complex
pathogen
engag
vari
epitop
multipl
diseaserel
antigen
eg
receptor
overcom
heterogen
plastic
oligoclon
antibodi
emerg
therapeut
format
novel
antibodi
combin
develop
singl
drug
product
provid
histor
context
use
oligoclon
antibodi
oncolog
infecti
diseas
highlight
practic
consider
relat
preclin
clinic
develop
program
combin
monoclon
antibodi
provid
promis
opportun
increas
patient
benefit
beyond
alreadi
observ
individu
mab
across
numer
diseas
area
includ
oncolog
infecti
diseas
autoimmun
combin
gener
retain
advantag
individu
mab
includ
wellcharacter
cellintrins
cellextrins
mechan
action
establish
manufactur
process
accept
safeti
profil
number
approv
antibodi
increas
seven
new
mab
approv
nearli
mab
late
stage
clinic
develop
ie
phase
approxim
new
mab
enter
phase
everi
year
like
number
clinic
studi
antibodi
combin
similarli
increas
oligoclon
antibodi
subset
broader
field
antibodi
combin
unlik
tradit
combin
mab
approv
sought
combin
use
two
separ
drug
product
oligoclon
antibodi
develop
singl
drug
product
defin
mixtur
mab
specifi
formul
ratio
biolog
rational
clinic
applic
combin
anticanc
mab
wellestablish
numer
studi
across
solid
hematolog
cancer
date
howev
two
pair
antibodi
receiv
regulatori
approv
use
combin
mab
trastuzumab
pertuzumab
breast
cancer
immunomodulatori
mab
ipilimumab
nivolumab
melanoma
two
success
stand
apart
multitud
studi
assess
clinic
benefit
combin
use
monoclon
antibodi
studi
notabl
includ
combin
use
approv
mab
egfr
cetuximab
panitumumab
trastuzumab
vegf
bevacizumab
across
cancer
indic
combin
use
agent
investig
mab
target
hgfcmet
clinic
data
combin
immunomodulatori
mab
still
immatur
studi
remain
ongo
excit
area
develop
antibodi
combin
combin
use
separ
drug
product
common
oncolog
two
oligoclon
mixtur
mab
clinic
develop
three
antiegfr
two
antiegfr
rational
potenti
applic
oligoclon
mab
could
parallel
within
context
infecti
diseas
antiinfect
antibodi
altern
therapeut
modal
antimicrobi
convent
antibiot
peptid
howev
effort
develop
antiinfect
antibodi
lag
behind
cancer
two
monoclon
antibodi
approv
diseas
area
palivizumab
prevent
rsv
infect
prematur
risk
newborn
raxibacumab
treatment
inhal
anthrax
addit
ongo
develop
new
mab
includ
radiolabel
mab
numer
ongo
preclin
clinic
studi
assess
util
tradit
oligoclon
combin
antiinfect
antibodi
oligoclon
antibodi
combin
infecti
diseas
statu
quo
develop
effect
therapeut
bacteri
viral
target
must
contend
varieti
primari
adapt
mechan
limit
activ
andor
durat
respons
oligoclon
antibodi
recogn
potenti
solut
challeng
signific
number
candid
undergo
develop
infecti
diseas
tabl
complex
pathogen
bacteria
harbor
redund
cell
surfac
andor
secret
virul
factor
evolv
resist
avail
drug
demonstr
increas
preval
multidrug
resist
gramposit
gramneg
bacteria
nosocomi
infect
pathogen
target
term
strain
coverag
involv
multipl
mechan
action
effect
combin
multipl
antibodi
exemplifi
develop
two
oligoclon
mixtur
two
mab
target
clostridium
difficil
exotoxin
b
anoth
exampl
oligoclon
mixtur
two
mab
fight
pneumonia
bloodstream
infect
caus
staphylococcu
aureu
mab
broadli
react
alphatoxin
fcompon
three
leukotoxin
luksf
luke
hlgb
second
mab
target
leukotoxin
lukab
yet
anoth
exampl
oligoclon
mixtur
two
antibodi
shiga
toxin
produc
escherichia
coli
caus
hemorrhag
coliti
hemolyticurem
syndrom
need
combin
multipl
antibodi
also
appli
serotypedepend
bacteri
target
oantigen
lipopolysaccharid
gramneg
bacteria
context
target
one
sever
serotyp
would
provid
overal
insuffici
coverag
eg
igm
antibodi
panobacumab
p
aeruginosa
oligoclon
mixtur
also
assess
viral
pathogen
order
neutral
highli
variabl
continu
drift
target
exampl
mixtur
two
antiinfect
antibodi
call
necessari
target
hemagglutinin
group
group
subtyp
influenza
present
altern
rare
antibodi
capabl
broadli
neutral
subtyp
gener
antibodi
broadli
react
highli
variabl
virus
influenza
viru
also
character
recognit
site
vulner
reduc
risk
pathogen
escap
case
less
variabl
pathogen
need
antibodi
combin
driven
risk
rare
natur
escap
variant
risk
select
vivo
escap
mutant
use
two
antibodi
nonoverlap
site
consid
possibl
solut
special
section
new
concept
antibodi
therapeut
tabl
oligoclon
antibodi
develop
infecti
diseas
problem
demonstr
rabi
viru
hbv
merscov
gener
scientif
rule
govern
ration
select
appropri
number
antibodi
oligoclon
mixtur
exampl
combin
multipl
antibodi
typic
three
show
signific
synergist
effect
vivo
case
antibodi
botulinum
neurotoxin
pertussi
toxin
anoth
exampl
case
three
antibodi
compos
zmapp
prepar
util
compassion
basi
recent
random
trial
howev
fail
show
statist
signific
effect
treat
ebola
viru
infect
recent
outbreak
west
africa
suggest
mechan
respons
observ
synergist
effect
increas
function
antibodi
bind
affin
combin
direct
neutral
antibodi
effector
function
fcdepend
hepat
clearanc
immunecomplex
similar
recent
observ
ige
gmcsf
gener
highord
oligoclon
mixtur
also
name
polyclon
due
high
number
antibodi
mixtur
pioneer
limit
number
compani
includ
symphogen
demonstr
mixtur
mab
target
vaccinia
viru
six
mab
rsv
rational
highord
mixtur
ceas
clinic
develop
state
recapitul
divers
specif
human
antibodi
immun
respons
oligoclon
antibodi
combin
oncolog
overcom
tumor
heterogen
plastic
divers
monoclon
antibodybas
therapeut
treatment
cancer
encompass
wide
class
agent
includ
antitumor
mab
eg
trastuzumab
pertuzumab
cetuximab
rituximab
inhibitor
angiogenesi
eg
bevacizumab
immunotherapi
eg
ipilimumab
nivolumab
antibodydrug
conjug
eg
adotrastuzumab
emtansin
brentuximab
vedotin
host
novel
format
mab
function
varieti
overlap
mechan
notabl
includ
perturb
cell
signal
respons
engag
immuneeffector
activ
eg
antibodydepend
cellular
cytotox
modul
host
immun
respons
applic
combin
agent
focu
intens
preclin
clinic
develop
highlight
necess
programmat
keyword
search
across
public
databas
gener
complet
account
combin
develop
antibodi
combin
contemporan
intim
depend
upon
advanc
molecular
profil
technolog
led
revolut
understand
genom
proteom
landscap
across
cancer
host
immun
system
eg
nextgener
sequenc
multiplex
immunohistochemistri
effort
linchpin
precis
medicin
strategi
reveal
univers
driver
gene
redund
within
across
cell
signal
pathway
inform
select
appropri
therapeut
combin
identif
predict
biomark
recent
longitudin
analysi
patient
sampl
across
cours
treatment
reveal
challeng
opportun
develop
therapeut
strategi
overcom
exploit
tumor
heterogen
evolut
plastic
regard
oncolog
share
core
biolog
context
infecti
diseas
thu
necess
recapitul
context
preclin
test
monitor
tumor
evolut
cours
treatment
eg
via
liquid
biopsi
analysi
cellfre
dna
use
oligoclon
antibodi
oncolog
still
emerg
rel
candid
develop
tabl
receptor
plastic
function
redund
two
exemplari
phenomena
address
current
oligoclon
antibodi
also
analog
biolog
infecti
diseas
aspect
perhap
better
studi
erbb
receptor
egfr
downstream
mapk
akt
effector
pathway
impress
number
preclin
clinic
studi
evalu
combin
target
therapi
includ
antibodi
smallmolecul
inhibitor
eg
tyrosin
kinas
inhibitor
within
core
cancer
pathway
oligoclon
antibodi
cancer
infecti
diseas
corti
kearn
first
monospecif
oligoclon
mixtur
demonstr
maintain
activ
presenc
somat
mutat
extracellular
domain
egfr
receptor
function
marker
primari
insensit
acquir
resist
singl
mab
cetuximab
panitumumab
trastuzumab
addit
mechan
action
monospecif
oligoclon
mixtur
beyond
alreadi
describ
robust
inhibit
cell
signal
enhanc
downregul
receptor
increas
activ
complementdepend
cytotox
notabl
oligoclon
mixtur
three
antiegfr
antibodi
demonstr
maintain
activ
cell
line
patientderiv
model
harbor
egfr
extracellular
domain
mutat
inhibit
bind
singl
antibodi
longitudin
analysi
cellfre
dna
liquid
biopsi
subcohort
patient
treat
reveal
chang
allel
frequenc
egfr
mutat
cours
treatment
hypothes
mixtur
multipl
mab
singleag
activ
case
perhap
requir
gener
suffici
therapeut
redund
overcom
receptor
plastic
inhibit
bind
one
mab
second
combin
antibodi
specif
differ
erbb
receptor
demonstr
preclin
model
overcom
primari
adapt
function
redund
via
signal
elsewher
erbbmapkakt
network
date
howev
combin
approv
therapeut
target
trastuzumab
cetuximab
egfr
shown
suffici
clinic
activ
seek
approv
combin
oligoclon
mixtur
six
antibodi
egfr
two
mab
per
receptor
repres
novel
approach
overcom
function
redund
across
multipl
target
remain
seen
futur
clinic
develop
gener
multispecif
oligoclon
antibodi
incorpor
diagnost
strategi
identifi
patient
whose
tumor
truli
depend
upon
target
antigen
eg
receptor
like
adapt
treatment
one
antigen
via
remain
antigen
humor
immun
respons
gener
polyclon
antibodi
respons
target
multipl
epitop
mediat
broad
varieti
effector
function
use
passiv
serotherapi
pioneer
emil
v
behr
kitasato
earli
show
hyperimmun
sera
anim
origin
could
protect
diphtheria
tetanu
approach
case
replac
use
hyperimmun
immunoglobulin
prepar
still
use
treat
sever
infecti
diseas
polyclon
antibodi
therapi
enter
clinic
develop
oncolog
technolog
hurdl
address
enabl
product
develop
methodolog
gener
librari
polyclon
antibodi
use
bloodderiv
polyclon
antibodi
face
obstacl
limit
avail
risk
bloodborn
diseas
transmiss
batchtobatch
variabl
importantli
low
specif
activ
small
fraction
antibodi
specif
antigen
interest
thu
requir
larg
dose
efficaci
one
advantag
recombin
oligoclon
antibodi
mixtur
natur
polyclon
respons
case
antibodi
cocktail
select
engin
tune
high
affin
neutral
activ
optim
effector
function
design
avoid
sink
effect
decoy
epitop
thu
allow
develop
antibodybas
product
abl
exceed
potenc
natur
polyclon
antibodi
anoth
advantag
oligoclon
antibodi
abil
ration
defin
optim
formul
ratio
basi
systemat
preclin
studi
eg
use
pairwis
titrat
purifi
compon
antibodi
without
signific
inconveni
gener
screen
multitud
polyclon
express
variant
combin
multipl
specif
singl
molecul
repres
altern
therapeut
strategi
oligoclon
antibodi
wide
number
multispecif
often
bispecif
antibodi
format
progress
clinic
develop
two
bispecif
antibodi
approv
use
oncolog
catumaxomab
eu
blinatumomab
us
util
bispecif
format
retarget
cell
tumor
cell
via
engag
epcam
respect
date
multispecif
product
approv
treatment
infecti
diseas
one
promis
candid
earli
clinic
develop
target
two
pseudomona
aeruginosa
cellsurfac
factor
psl
pcrv
show
enhanc
activ
comparison
combin
parent
antibodi
evid
suggest
multispecif
antibodi
harbor
gener
advantag
combin
monospecif
antibodi
contrari
understood
select
appropri
therapeut
format
depend
upon
factor
target
engag
eg
target
requir
biolog
context
eg
antigen
coexpress
cell
antigen
express
distinct
cell
cell
close
proxim
must
consid
earli
preclin
develop
exampl
antibodi
mixtur
show
higher
efficaci
compar
correspond
bispecif
antibodi
case
combin
antibodi
target
cellsurfac
molecul
secret
toxin
dc
unpublish
result
scenario
one
two
target
might
exhibit
sink
effect
second
antibodi
polyclon
antibodi
regul
center
biolog
evalu
research
cber
regul
requir
character
bulk
activ
product
individu
antibodi
similar
consider
appli
regul
multival
vaccin
requir
assess
individu
vaccin
antigen
compon
howev
recombin
biolog
regul
center
drug
evalu
research
cder
differ
rule
appli
gener
oligoclon
recombin
antibodi
regul
accord
combin
drug
rule
fda
ema
guidelin
rule
indic
compon
combin
product
assess
individu
well
combin
gener
may
requir
assess
safeti
pharmacokinet
potenti
efficaci
multiarm
clinic
studi
assess
individu
antibodi
compon
late
stage
multiarm
trial
pose
obviou
clinic
financi
obstacl
especi
combinatori
submixtur
includ
importantli
develop
therapeut
current
guidanc
specifi
requir
may
waiv
ethic
ground
suffici
preclin
clinic
data
indic
monotherapi
would
like
ineffect
case
primari
andor
acquir
resist
signific
concern
inde
fda
sever
occas
allow
oligoclon
antibodi
clinic
test
singl
product
phase
phase
studi
rabi
botulinum
rhesu
antigen
antiegfr
therapeut
cancer
oligoclon
antibodi
date
file
regulatori
approv
recommend
sponsor
engag
regul
earli
often
develop
product
warrant
share
experi
commun
product
recombin
oligoclon
antibodi
larg
extens
wellestablish
practic
util
individu
mab
date
major
disclos
oligoclon
antibodi
product
util
parallel
gmp
manufactur
approach
mab
express
purifi
individu
subsequ
formul
singl
vial
rare
mab
combin
point
administr
illustr
earli
clinic
evalu
three
broadli
neutral
antibodi
administ
serial
infus
socal
singl
pot
strategi
repres
altern
approach
product
oligoclon
mixtur
compon
antibodi
inher
combin
downstream
singl
pot
product
strategi
util
mixtur
antibodyproduc
cell
line
singl
bioreactor
sever
singl
pot
technolog
platform
develop
overcom
challeng
reproduc
cell
growth
constant
antibodi
ratio
meru
develop
platform
util
cell
stabli
express
one
common
light
chain
three
heavi
chain
limit
product
oligoclon
antibodi
includ
antigen
specif
via
light
chain
second
approach
develop
symphogen
base
site
specif
integr
antibodi
express
cassett
order
favor
consist
growth
express
eg
express
antibodi
product
call
rozrolimupab
test
phase
treatment
primari
immun
thrombocytopenia
purpura
variant
second
approach
also
develop
symphogen
base
random
integr
select
high
express
stabl
clone
use
singl
pot
product
shown
case
rsv
vaccinia
viru
oligoclon
antibodi
product
develop
oligoclon
antibodi
involv
sever
uniqu
challeng
must
consid
key
decis
point
start
earli
therapeut
design
preclin
test
continu
clinic
studi
figur
consider
describ
repres
certainli
challeng
pharmacokinet
compon
antibodi
oligoclon
antibodi
product
consist
formul
compon
mab
ratio
within
rang
ratio
defin
time
initi
regulatori
file
eg
ind
howev
problemat
assum
formul
ratio
maintain
patient
due
potenti
differenti
pharmacokinet
adm
ie
absorpt
distribut
metabol
excret
antibodi
character
mitig
issu
must
essenti
factor
develop
oligoclon
antibodi
preclin
research
perform
mixtur
assess
physiolog
relev
rang
ratio
ensur
activ
maintain
clinic
studi
select
dose
dose
interv
consid
pharmacokinet
individu
compon
antibodi
use
antibodyspecif
assay
ensur
activ
ratio
maintain
time
across
patient
issu
exemplifi
use
oligoclon
antibodi
multipl
antigen
describ
mediat
differ
degre
targetmedi
drug
disposit
tmdd
exampl
reason
expect
equimolar
ratio
six
antibodi
combin
vari
time
due
signific
via
egfr
neglig
tmdd
via
risk
may
appli
also
antiinfect
antibodi
multipl
antigen
target
could
display
differ
variabl
level
depend
multipl
factor
influenc
pathogen
growth
clearanc
overlap
toxic
profil
similar
combin
drug
treatment
oligoclon
antibodi
harbor
potenti
overlap
toxic
profil
may
difficult
interpret
mitig
clinic
adjust
defin
formul
ratio
regularli
done
combin
use
separ
mab
drug
product
perhap
press
anticanc
antibodi
must
contend
selfrecognit
less
press
antiinfect
antibodi
inher
advantag
specif
pathogen
antigen
inde
antiinfect
oligoclon
antibodi
commonli
test
safeti
phase
studi
healthi
patient
two
practic
consider
develop
oligoclon
antibodi
underli
biolog
diseas
context
inform
therapeut
design
gener
proofofconcept
molecul
key
consider
select
monospecif
multispecif
antibodi
b
comprehens
preclin
assess
perform
relev
model
system
character
perform
individu
mab
mixtur
emerg
properti
mixtur
find
like
iter
inform
therapeut
design
c
select
formul
ratio
ratio
antibodi
within
mixtur
perhap
critic
decis
point
develop
oligoclon
antibodi
strongli
coupl
preclin
test
manufactur
consider
later
clinic
develop
numer
manufactur
strategi
oligoclon
antibodi
notabl
parallel
gmp
singl
pot
inform
formul
ratio
commerci
consider
assess
pharmacokinet
safeti
preclin
e
clinic
f
studi
consid
individu
mab
well
mixtur
unexpect
find
rapid
clearanc
limit
therapeut
window
individu
antibodi
may
necessit
costli
time
consum
reconsider
formul
ratio
g
clinic
develop
strategi
includ
strong
consider
regulatori
landscap
ensur
suffici
data
gener
support
mixtur
eg
improv
activ
mixtur
versu
individu
antibodi
andor
applic
waiver
combin
drug
rule
instanc
approv
combin
use
separ
mab
oncolog
util
monotherapi
dose
mab
eg
trastuzumab
pertuzumab
nivolumab
ipilimumab
rigor
preclin
earli
clinic
toxicolog
studi
perform
oligoclon
antibodi
identifi
issu
would
motiv
reformul
like
necessit
new
ind
file
discontinu
overlap
elus
mechan
action
oligoclon
antibodi
demonstr
sever
mechan
action
uniqu
mixtur
engag
immun
respons
enhanc
receptor
downregul
increas
clearanc
immun
complex
toler
escap
variant
acquir
resist
mechan
character
emerg
properti
individu
combin
trivial
complic
need
comprehens
model
system
exampl
standard
human
xenograft
tumor
model
mask
enhanc
immun
activ
implant
immunedefici
mous
tumor
microenviron
effect
one
antibodi
crossreact
mous
antigen
oligoclon
character
strategi
consid
earli
develop
like
inform
decis
therapeut
design
select
formul
ratio
eg
speci
crossreact
consid
lead
select
translat
preclin
find
clinic
develop
inher
risk
develop
oligoclon
antibodi
necess
complet
comprehens
preclin
data
packag
support
combin
antibodi
formul
ratio
beyond
commerci
manufactur
consider
key
differenti
combin
separ
antibodi
product
develop
oligoclon
antibodi
would
wise
priorit
earli
preclin
effort
ongo
translat
research
latestag
failur
combin
two
antibodi
clostridium
difficil
toxin
b
actoxumab
bezlotoxumab
technic
oligoclon
antibodi
cautionari
tale
oligoclon
antibodi
experi
highlight
need
clearli
demonstr
necess
oligoclon
antibodi
modal
rigor
preclin
studi
relev
model
initi
anim
studi
demonstr
enhanc
activ
combin
motiv
phase
trial
assess
activ
combin
individu
antibodi
howev
later
result
two
compar
phase
clinic
trial
modifi
ii
reveal
benefit
combin
toxin
bspecif
mab
alon
bezlotoxumab
inde
subsequ
anim
studi
use
isogen
toxin
b
mutant
virul
c
difficil
strain
demonstr
toxin
b
essenti
virul
conceptu
util
oligoclon
antibodi
treatment
infecti
diseas
cancer
support
grow
list
investig
agent
undergo
clinic
develop
diseas
area
nevertheless
therapeut
yet
establish
clinic
util
product
receiv
regulatori
approv
date
increas
scientif
develop
focu
oligoclon
antibodi
howev
suggest
field
approach
watersh
moment
review
highlight
biolog
context
practic
consider
exist
oligoclon
antibodi
realiz
throughout
develop
program
particular
note
import
comprehens
preclin
data
packag
support
oligoclon
format
formul
ratio
key
differenti
tradit
antibodi
combin
readili
adjust
base
upon
compar
clinic
studi
comprehens
preclin
clinic
strategi
address
consider
like
posit
effect
develop
oligoclon
antibodi
across
diseas
area
